Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04566432

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Sponsor: Geneplus-Beijing Co. Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.

Official title: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICIs) or Targeted Therapy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

250

Start Date

2020-07-01

Completion Date

2025-06-30

Last Updated

2024-07-18

Healthy Volunteers

No

Interventions

OTHER

Observation

observe the association of ctDNA with efficacy of treatment

Locations (1)

Shanghai Chest Hospital

Shanghai, China